Abstract 1495P
Background
Socially isolated patients have a higher early mortality rate across multiple cancers. However, there have been no reports on how social isolation such as solitary life affects the clinical outcomes in advanced non-small cell lung cancer (NSCLC).
Methods
We conducted a retrospective analysis of patients with advanced NSCLC who received systemic therapy at the National Cancer Center (NCC) between January 2021 and December 2023. This study assessed the association between social isolation, such as living alone, and clinical outcomes, including overall survival (OS) and the incidence of serious adverse events (SAE) during systemic treatment. Additionally, we evaluated the transition rates to palliative care, both at home and in palliative care units (PCU), as well as the proportion of in-hospital deaths at our institution.
Results
During the study period, 679 patients initiated systemic treatment for advanced NSCLC. Of these, 119 patients were living alone (alone group) while the remaining 560 were not (non-alone group). The median age was comparable between the alone and non-alone groups (63 vs. 67 years, p=0.20), but the alone group had a higher proportion of females (46.2% vs. 37.5%, p=0.08). Regarding the driver genetic alterations, there was no significant difference between the two groups in the presence of EGFR mutations (36.1% vs. 32.1%, p=0.70) and ALK rearrangement (7.4% vs. 5.3%, p=0.66). Treatment modalities were also comparable between the alone group and non-alone groups for TKI use (44.1% vs. 39.5%, p=0.86). The alone group showed numerically better outcomes in OS and SAE rates than the non-alone group (OS: not reached vs. 50.7 months, p=0.11; and SAE: 10.9% vs. 18.8%, p=0.08). In the alone group, the transition rates to palliative care at home was significantly lower (13.0% vs. 32.0%, p=0.04), and the proportion of in-hospital deaths (NCC or PCU) was higher compared with non-alone group (82.6% vs. 66.7%, p=0.04).
Conclusions
Social isolation such as living alone did not affect the clinical outcomes such as OS and SAE during the systemic treatment in advanced NSCLC patients. However, it did influence the palliative care practices, resulting in a higher rate of hospital deaths.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
T.Yoshida.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1564P - Limited participation in breast cancer screening among low-SES women: A matter of engagement or of health literacy?
Presenter: Allegra Ferrari
Session: Poster session 10
1566P - Optimizing participation in lung cancer screening program: Results from the first round in ILYAD study in Lyon University Hospital
Presenter: Emmanuel Grolleau
Session: Poster session 10
1567P - Physicians' adenoma detection rate and the risk of colorectal cancer in sequential screening programs: An observational cohort study
Presenter: Li Xie
Session: Poster session 10
1568P - Challenges in pilot lung cancer screening in Vojvodina, Serbia
Presenter: Jelena Djekic Malbasa
Session: Poster session 10
1569P - Secondary delay in breast cancer diagnosis and role of rural medical practitioners: A cause and cure finding study
Presenter: Rahul Agarwal
Session: Poster session 10
1570P - Factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in China
Presenter: Yinghua Ji
Session: Poster session 10
1571P - The reasons that motivate a change of specialties among oncology residents
Presenter: Christophe Ducrocq
Session: Poster session 10
1572P - Factors associated with career choice in oncology among medical students
Presenter: Nicolas Penel
Session: Poster session 10
1573P - Global cancer statistics for adolescents and young adults: New estimates from GLOBOCAN 2022
Presenter: Wang-Zhong Li
Session: Poster session 10
Resources:
Abstract